LY 191704

Drug Profile

LY 191704

Latest Information Update: 06 Jun 2001

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antiandrogens; Quinolones; Small molecules
  • Mechanism of Action Cholestenone 5-alpha reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Alopecia; Benign prostatic hyperplasia

Most Recent Events

  • 06 Jun 2001 No-Development-Reported for Alopecia in USA (Unknown route)
  • 06 Jun 2001 No-Development-Reported for Benign prostatic hyperplasia in USA (Unknown route)
  • 16 Apr 1998 Preclinical development for Benign prostatic hyperplasia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top